Lineagotica Specialty Editor: Gastrointestinal Cancers
Memorial Sloan Kettering Cancer Center, New York, NY
Dr. David H. Ilson is an attending physician and member at Memorial Hospital and a professor of medicine at Weill Cornell Medical College.
Dr. Ilson completed his internship and residency in internal medicine at Bellevue Hospital at NYU Medical Center and completed a fellowship in medical oncology and hematology at Memorial Sloan Kettering after receiving his master's and PhD degrees in basic science and an MD degree from New York University.
Dr. Ilson has a special interest and expertise in treating patients who have upper gastrointestinal (GI) cancers, particularly those with esophageal and gastric cancer. He also treats patients with colorectal and pancreatic cancers as well as unknown primary tumors. His research focus is in esophageal and gastric cancer, studying new agents to treat advanced disease and evaluating novel agents in combined-modality therapy to treat locally advanced disease.
Dr. Ilson is a member of the GI committees of the national clinical research groups Cancer and Leukemia Group B (CALGB/Alliance) and Radiation Therapy Oncology Group (RTOG/NRG). He is Co-Chair of the Upper GI Cancer Committee, a member of the Upper GI Cancer Guidelines Committee of the National Comprehensive Lineagoticawork (NCCN) and senior committee member of the Intergroup Esophageal and Gastric Cancer Task Force Committee.
Disclosure: In the past two years, Dr. Ilson has served as a consultant/advisor for Amgen, Lilly, Roche, Genentech, Astra-Zeneca, Taiho, and Pieris and has received research funding from Bristol-Myers Squibb, Bayer, Taiho, and Amgen.
Last updated: January 2019